The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades

被引:177
作者
Mendez, Joe S. [1 ]
Ostrom, Quinn T. [2 ,3 ]
Gittleman, Haley [2 ,3 ]
Kruchko, Carol [3 ]
DeAngelis, Lisa M. [1 ,4 ]
Barnholtz-Sloan, Jill S. [2 ,3 ]
Grommes, Christian [1 ,4 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10065 USA
[2] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA
[3] Cent Brain Tumor Registry US, Hinsdale, IL USA
[4] Weill Cornell Med Sch, Dept Neurol, New York, NY USA
关键词
CBTRUS; incidence; primary CNS lymphoma (PCNSL); SEER; survival; PRIMARY CNS LYMPHOMA; INTERNATIONAL EXTRANODAL LYMPHOMA; WHOLE-BRAIN RADIOTHERAPY; KETTERING CANCER CENTER; HIGH-DOSE CHEMOTHERAPY; PHASE-2; TRIAL; METHOTREXATE; POPULATION; CYTARABINE; PROCARBAZINE;
D O I
10.1093/neuonc/nox187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There has been significant improvement in treatment outcomes of primary central nervous system lymphoma (PCNSL) at specialized centers over the past several decades; however, it is unclear if these changes have translated to benefits in the general population. In this study, we utilized 2 national databases to examine survival trends over time for PCNSL: the Central Brain Tumor Registry of the United States (CBTRUS, 2000-2013) and 18 registries from the Surveillance, Epidemiology, and End Results program (SEER, 1973-2013). The annual incidence of PCNSL in 2013 was 0.4 per 100000 population (CBTRUS/SEER). Incidence increased from 0.1 per 100000 in the 1970s to 0.4 per 100000 in the 1980s, correlating with an increase in the diagnosis of patients >= 70 years (1973: 0.2 vs 2013: 2.1 [SEER]). Incidence rates differed greatly between young and elderly patients (age 20-29 y: 0.08 vs 70-79 y: 4.32 [CBTRUS]). Even though the median overall survival of all patients doubled from 12.5 months in the 1970s to 26 months in the 2010s, this survival benefit was limited to patients < 70 years. Survival in the elderly population has not changed in the last 40 years (6 mo in the 1970s vs 7 mo in the 2010s, P = 0.1). The poor outcome seen in the particularly vulnerable elderly patient population highlights the need for clinical trials targeting the elderly in hopes of improving treatment strategies and survival.
引用
收藏
页码:687 / 694
页数:8
相关论文
共 25 条
  • [1] Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model
    Abrey, Lauren E.
    Ben-Porat, Leah
    Panageas, Katherine S.
    Yahalom, Joachim
    Berkey, Brian
    Curran, Walter
    Schultz, Christopher
    Leibel, Steven
    Nelson, Diana
    Mehta, Minesh
    DeAngelis, Lisa M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) : 5711 - 5715
  • [2] COMBINED MODALITY THERAPY FOR PRIMARY CNS LYMPHOMA
    DEANGELIS, LM
    YAHALOM, J
    THALER, HT
    KHER, U
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) : 635 - 643
  • [3] EBY NL, 1988, CANCER-AM CANCER SOC, V62, P2461, DOI 10.1002/1097-0142(19881201)62:11<2461::AID-CNCR2820621135>3.0.CO
  • [4] 2-M
  • [5] Prognostic scoring system for primary CNS lymphomas: The international extranodal lymphoma study group experience
    Ferreri, AJM
    Blay, JY
    Reni, M
    Pasini, F
    Spina, M
    Ambrosetti, A
    Calderoni, A
    Rossi, A
    Vavassori, V
    Conconi, A
    Devizzi, L
    Berger, F
    Ponzoni, M
    Borisch, B
    Tinguely, M
    Cerati, M
    Milani, M
    Orvieto, E
    Sanchez, J
    Chevreau, C
    Dell'Oro, S
    Zucca, E
    Cavalli, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 266 - 272
  • [6] Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
    Ferreri, Andres J. M.
    Cwynarski, Kate
    Pulczynski, Elko
    Ponzoni, Mourilio
    Deckert, Martina
    Politi, Letterio S.
    Torri, Valter
    Fox, Christopher P.
    La Rosee, Paul
    Schorb, Elisabeth
    Ambrosetti, Achille
    Roth, Alexander
    Hemmoway, Claire
    Ferrari, Angela
    Linton, Kim M.
    Ruda, Roberta
    Binder, Mascha
    Pukrop, Tobias
    Balzarotti, Monica
    Fabbri, Alberto
    Johnson, Peter
    Gorlov, Jette Sonderskov
    Hess, Georg
    Panse, Jens
    Pisani, Francesco
    Tucci, Alessandra
    Stilgenbauer, Stephan
    Hertenstein, Bernd
    Keller, Ulrich
    Krause, Stefan W.
    Levis, Alessandro
    Schmoll, Hans J.
    Covalli, Franco
    Finke, Jurgen
    Reni, Michele
    Zucca, Emanuele
    Illerhaus, Gerald
    [J]. LANCET HAEMATOLOGY, 2016, 3 (05): : E217 - E227
  • [7] High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
    Fritsch, K.
    Kasenda, B.
    Schorb, E.
    Hau, P.
    Bloehdorn, J.
    Moehle, R.
    Loew, S.
    Binder, M.
    Atta, J.
    Keller, U.
    Wolf, H-H
    Krause, S. W.
    Hess, G.
    Naumann, R.
    Sasse, S.
    Hirt, C.
    Lamprecht, M.
    Martens, U.
    Morgner, A.
    Panse, J.
    Frickhofen, N.
    Roeth, A.
    Hader, C.
    Deckert, M.
    Fricker, H.
    Ihorst, G.
    Finke, J.
    Illerhaus, G.
    [J]. LEUKEMIA, 2017, 31 (04) : 846 - 852
  • [8] PREIRRADIATION METHOTREXATE CHEMOTHERAPY OF PRIMARY CENTRAL-NERVOUS-SYSTEM LYMPHOMA - LONG-TERM OUTCOME
    GLASS, J
    GRUBER, ML
    CHER, L
    HOCHBERG, FH
    [J]. JOURNAL OF NEUROSURGERY, 1994, 81 (02) : 188 - 195
  • [9] Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227
    Glass, Jon
    Won, Minhee
    Schultz, Christopher J.
    Brat, Daniel
    Bartlett, Nancy L.
    Suh, John H.
    Werner-Wasik, Maria
    Fisher, Barbara Jean
    Liepman, Marcia K.
    Augspurger, Mark
    Bokstein, Felix
    Bovi, Joseph A.
    Solhjem, Matthew C.
    Mehta, Minesh P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1620 - U142
  • [10] High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
    Illerhaus, Gerald
    Kasenda, Benjamin
    Ihorst, Gabriele
    Egerer, Gerlinde
    Lamprecht, Monika
    Keller, Ulrich
    Wolf, Hans-Heinrich
    Hirt, Carsten
    Stilgenbauer, Stephan
    Binder, Mascha
    Hau, Peter
    Edinger, Matthias
    Frickhofen, Norbert
    Bentz, Martin
    Moehle, Robert
    Roeth, Alexander
    Pfreundschuh, Michael
    von Baumgarten, Louisa
    Deckert, Martina
    Hader, Claudia
    Fricker, Heidi
    Valk, Elke
    Schorb, Elisabeth
    Fritsch, Kristina
    Finke, Juergen
    [J]. Lancet Haematology, 2016, 3 (08): : E388 - E397